1. Home
  2. CINT vs NTLA Comparison

CINT vs NTLA Comparison

Compare CINT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINT
  • NTLA
  • Stock Information
  • Founded
  • CINT 1995
  • NTLA 2014
  • Country
  • CINT Brazil
  • NTLA United States
  • Employees
  • CINT N/A
  • NTLA N/A
  • Industry
  • CINT EDP Services
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CINT Technology
  • NTLA Health Care
  • Exchange
  • CINT Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • CINT 803.4M
  • NTLA 794.5M
  • IPO Year
  • CINT 2021
  • NTLA 2016
  • Fundamental
  • Price
  • CINT $5.70
  • NTLA $11.54
  • Analyst Decision
  • CINT Buy
  • NTLA Buy
  • Analyst Count
  • CINT 7
  • NTLA 19
  • Target Price
  • CINT $7.61
  • NTLA $35.11
  • AVG Volume (30 Days)
  • CINT 92.5K
  • NTLA 4.8M
  • Earning Date
  • CINT 08-15-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • CINT N/A
  • NTLA N/A
  • EPS Growth
  • CINT 53.80
  • NTLA N/A
  • EPS
  • CINT 0.24
  • NTLA N/A
  • Revenue
  • CINT $444,135,000.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • CINT $526.02
  • NTLA N/A
  • Revenue Next Year
  • CINT $12.77
  • NTLA N/A
  • P/E Ratio
  • CINT $23.81
  • NTLA N/A
  • Revenue Growth
  • CINT 3.04
  • NTLA N/A
  • 52 Week Low
  • CINT $4.42
  • NTLA $5.90
  • 52 Week High
  • CINT $8.04
  • NTLA $28.18
  • Technical
  • Relative Strength Index (RSI)
  • CINT 43.28
  • NTLA 65.96
  • Support Level
  • CINT $5.89
  • NTLA $10.19
  • Resistance Level
  • CINT $5.94
  • NTLA $12.34
  • Average True Range (ATR)
  • CINT 0.16
  • NTLA 0.69
  • MACD
  • CINT -0.01
  • NTLA 0.22
  • Stochastic Oscillator
  • CINT 4.65
  • NTLA 76.77

About CINT CI&T Inc

CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: